{
    "id": "6kyxirbeegfasl7eryfsdhwbkykic4ns",
    "title": "The time of the ALSFRS-R to decrease to 50% (D50) in a sigmoidal decay model sufficiently describes the complete disease course of ALS",
    "info": {
        "author": [
            "Nayana Gaur, Jena University Hospital"
        ],
        "published": "July 21, 2017",
        "recorded": "May 2017",
        "category": [
            "Top->Medicine",
            "Top->Medicine->Neuroscience"
        ]
    },
    "url": "http://videolectures.net/encals2017_gaur_sigmoidal_decay_model/",
    "segmentation": [
        [
            "Good afternoon everyone.",
            "My name is Nana Gore and I am a first year PhD student at the Department of Neurology at Vienna University Hospital.",
            "I would like to actually first begin by saying I'm very humbled by and grateful for the opportunity to be speaking amongst Giants in the field, and such an accomplished audience.",
            "So today I hope to be able to adequately convince you of the utility and relevance of a novel Indies to track both progression and describe the disease scores of Amaya trophic lateral sclerosis.",
            "So."
        ],
        [
            "We know that the LSF RSR is a questionnaire that is routinely used to track functional deterioration within the disease.",
            "It uses 12 questions that map to four key domains.",
            "Bulbar fine motor breathing and gross motor.",
            "It has been successfully used up to now.",
            "I might add from the LS, FRS, Arcam Delta efforts this was put forth by the Kimora Group in 2006 and they offered a way to track the rate of progression by including a time axis.",
            "As you can see, sorry with the form.",
            "I'm sorry the formula with the formula over here.",
            "Now, when this was conceptualized, it was intended to be used only at the time of diagnosis, but this has now expanded to be used routinely in clinical trials to stratify patients as either fast, slow, or intermediate progressors.",
            "There are, however, several problems with using the Delta FRS in this way, and in the interest of time I will speak about only the most salient ones now."
        ],
        [
            "A quick an admittedly very perfunctory pub Med search actually makes my point for me excellently.",
            "We know that there is no established threshold which represents an important transitional point in functional status or progression type you can see here just for papers that I picked randomly and see how each of them define slow and fast progression with different thresholds.",
            "In fact, I recall a speech from earlier today that used 1.1 as the threshold, so we see that there is absolutely no agreement.",
            "But let's assume for a minute that we did have this threshold.",
            "This would still not rid us of our Delta.",
            "FRS was simply becausw."
        ],
        [
            "This graph, taken from our own cohort mapping LSF.",
            "Our score LSF score against disease duration tells us what we already know owing to the large body of work that precedes my talk, we know that progression is heterogeneous.",
            "It is nonlinear, but the Delta FRS presumes linearity.",
            "And it doesn't stop here.",
            "Not only is progression heterogeneous, it can actually vary within individuals across time and across the disease course."
        ],
        [
            "We can see here 3 individuals, let's call the red one.",
            "Fast intermediate is blue and slowest green.",
            "You can see just for these three individuals how much the Delta FOS varies across across different months across the disease scores.",
            "In fact, what's crucial is over here, how big the variation is within the first 12 months, which is actually crucial for clinical trial recruitment and the box that you are simply sums up.",
            "What I am telling you, there is tremendous variation and we simply can't use the Delta FRS like this."
        ],
        [
            "Which is where we come in.",
            "We present you two novel indices, D50 and DX, as an alternative to track progression and describe disease scores from full health, which would be hypothetically and LSF.",
            "Our score of 48, which is the maximum and disease within relentlessly deteriorating score.",
            "Now the D50 is simply the time taken for LSF SAR to drop to 50%, which would be a score of 24 the DX simply.",
            "Refers to the slope of this decrease."
        ],
        [
            "Both of these indices are derived from regularly collected LSF scores.",
            "As you can see in this next clip over here, I'm not sure how to so getting back I we were basically saying the D50 and DX are both ascertained from regularly regularly collected a LSF scores and we can give you a brief visualization.",
            "Over here.",
            "Now you can see the linearity already between D50 and DX, and this keeps building with as we include more patients now moving on well.",
            "You may immediately be inclined."
        ],
        [
            "I see, well, that's all very good, and that's a very nice little clip that you have.",
            "But how well does this hold up if we simply don't have as many LS Fr scores an I'm sure a number of you can speak to how difficult it is to retain patients over longitudinal trials.",
            "Failing health being, I suppose, the primary reason.",
            "So let's take a look.",
            "This is how well the linearity would hold up if I had access to only one FRS score for patient.",
            "This if I had two scores, if I had.",
            "Race course, or if I had 4 scores.",
            "The take home here is OK.",
            "Yes, there is much more noise as the number of scores available increase.",
            "But this linear relationship does not change.",
            "So although we do rely on LSF scores, the model is designed in such a way that it will still work even if you don't have access to as many."
        ],
        [
            "Now let's go back to the same three patients that we looked at earlier when we were talking about Delta Ephorus.",
            "Only this time we're going to talk about D50 and DX.",
            "Now, as you would expect, our fast Progressor has a much smaller D50 than, say you're slow.",
            "Progressor, almost half of it.",
            "Your intermediate progressor is somewhere in between, and here you have your DX, or your rate of decrease.",
            "But you may still ask the question.",
            "OK, we have a new way to track progression.",
            "We have a new way to describe these patients, but what about comparability?",
            "Say, how do I understand the disease mechanisms that_different phases of the disease without paying heed to rate of progression?",
            "How do we do it in spite differing rates of progression if we simply take these three curves?",
            "I'm sorry."
        ],
        [
            "And then normalize the absolute months for each patient across the disease scores by their individual D50 values.",
            "We immediately see they follow a similar pattern.",
            "Now, it doesn't matter whether I call them fast, intermediate, slow, good, bad, they will all follow a similar pattern we see here in the first stage, the LS of the LSF score doesn't plummet.",
            "Rather it starts to gradually decay, and this is approximately where patient start being rich.",
            "Recruited for Childs.",
            "The score goes on to eventually plateau out and we can see that you have a rather predictable pattern over here and this allows us to loosely."
        ],
        [
            "Classify four phases.",
            "You have the early stable phase early progressive phase, late progressive phase and late stable phase.",
            "Now the crucial thing about this phase classification is that it is fluid.",
            "It is mathematically derived from D50 values.",
            "So as of now our analysis has been constricted to our cohort.",
            "But say in the in the future, if we expanded this anet would an our results tell us it isn't in fact 50 by two or D53 by two we can change this to accommodate.",
            "What more more patients would tell us?"
        ],
        [
            "We then asked ourselves a question.",
            "While there are other staging systems already, we have the clinical King staging system.",
            "We have the functional my to staging system.",
            "Where do we fit into this picture?",
            "How can we understand our model in the context of these models?",
            "Now if you see here, we simply took 20 patients from our cohort and we manually stage them to both to either King stages or mitosis stages for both.",
            "For all of these patients, we calculated something called milestone timing.",
            "Now, this is simply the time taken to reach a particular stage or phase as a proportion of the total disease duration.",
            "The reason we kept it to 20 is because such a calculation is of course only possible with people who have traversed the entire disease scores or died.",
            "Now what you see immediately is that there is more agreement between the D50 system and the might or system.",
            "Now this is expected because these are both functional systems that are that use a LSF scores as their basis.",
            "What you also see as is at both of these systems seem to lag behind the King system.",
            "Simply you would reach phases later if you use the D50 or might or system.",
            "This is also this is understandable because the King system reflects disease burden.",
            "Clinical spread so naturally functional engagement follows anatomical involvement.",
            "This is what we see.",
            "We also notice that it was difficult for us to explicitly demonstrate.",
            "Sorry, this doesn't a stage one for the Kings.",
            "For the King system, and this is something the authors themselves noted as well by the time patients present, they are typically already at stage two where there is already involvement in the second region.",
            "So moving on."
        ],
        [
            "So what are our key takeaways from here?",
            "We know the D50 and DX are highly linear, which tells us D50 can act as a standalone parameter.",
            "It's accessible and it's destructive, and it's easy to use.",
            "More importantly, you may ask, well, can you give me something more robust in that we also see the D50 correlates very well with survival, which is the endpoint of choice in most clinical trials.",
            "We also see.",
            "That D50 and Delta FRS correlate very well as well.",
            "Now this over here is Delta FRS that was recorded for patients when they first presented and this over here is Delta FRS.",
            "Towards the end of the disease scores for them.",
            "Now this first graph simply sums up what I already told you earlier in the presentation that there is tremendous variation in Del Dia for us if I simply transform these Delta FOS values, say if I did this one over Delta FRS and then looked.",
            "At this correlation with D50 you see immediately a nice clean linear relationship, and again it correlates much better with the Delta FRS towards the end of the patients disease scores.",
            "Now what is crucial is that sampling.",
            "Say if I took a clinical sample at any point of the patients disease scores, it can always be viewed in context of the patients D50 rather than relying on Delta FOS, which may have changed at any point in the disease course."
        ],
        [
            "Now you may ask what is well, what's the take home message?",
            "How do we use this?",
            "What do we do with it?",
            "First of all, I have, as we've already seen, you can map and describe disease scores with mathematically fluid phases.",
            "The D50 provides value over and above raw Fr S scores for disease progression.",
            "We also know that there's increased analytical utility simply because it is such an easy endpoint for researchers to use.",
            "And finally, in what is most relevant for our group is biomarker development and testing, and this is something we are actively doing within our own group.",
            "For example, our recent work.",
            "This was published in neurology as well.",
            "Looked at how neurofilament levels are distributed across different phases of the disease and how it correlate's with the 15 you can see here that there is a difference between phase one and phase two.",
            "Other other members of our group are looking at dry biomarkers in your image Ng markers to see how white matter may change a white matter.",
            "Changes are different in either phase one or phase two of the disease.",
            "For example.",
            "Over here we see the changes are restricted more to the subcortical motor regions in the brain stem, whereas in phase two the later phase it starts to become more parietal and frontal.",
            "Finally, and I think crucially for everyone here we can understand disease mechanisms if in different phases.",
            "We know that there are different pathogenic mechanisms at play.",
            "Early in disease and later in the disease.",
            "And now we now have a way to understand them and study them."
        ],
        [
            "Finally, open questions and things that we're still looking to do.",
            "Of course, our first goal would be to expand the cohort we used to drive these indices and also replicated with much larger cohorts.",
            "We would also be interested in establishing actual mathematical cut offs for fast versus slow, for example, at what D50 value would I consider you to be a fast progressor, an intermediate progressor or slow progressor?",
            "We would also like to investigate the utility of these indices in clinical trial populations an genreless populations we also think.",
            "It would be worthwhile to further understand the role our system plays in the context of other current staging systems.",
            "We would also think we also think it would be relevant to apply stratification and stratify patients by say, for example site of onset, phenotype, etc.",
            "And finally we would like to test relation to other clinical factors.",
            "How does D50 correspond to muscle strength, quality of life, forced vital capacity or cognitive decline?",
            "We are also taking any suggestions for other than D50 Jena system.",
            "We would be happy to hear them."
        ],
        [
            "Acknowledgements so I would of course like to thank our funding bodies an all of our collaborators I would like to thank my supervisor, Doctor Union Gross Kreutz, my colleagues, Doctor Beatrice Tube, and Orphan Vagina for their support.",
            "Our clinical nurses and obviously our patients without whom none of this work would be possible.",
            "Thank you."
        ]
    ],
    "summarization": {
        "clip_0": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Good afternoon everyone.",
                    "label": 0
                },
                {
                    "sent": "My name is Nana Gore and I am a first year PhD student at the Department of Neurology at Vienna University Hospital.",
                    "label": 1
                },
                {
                    "sent": "I would like to actually first begin by saying I'm very humbled by and grateful for the opportunity to be speaking amongst Giants in the field, and such an accomplished audience.",
                    "label": 0
                },
                {
                    "sent": "So today I hope to be able to adequately convince you of the utility and relevance of a novel Indies to track both progression and describe the disease scores of Amaya trophic lateral sclerosis.",
                    "label": 0
                },
                {
                    "sent": "So.",
                    "label": 0
                }
            ]
        },
        "clip_1": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "We know that the LSF RSR is a questionnaire that is routinely used to track functional deterioration within the disease.",
                    "label": 0
                },
                {
                    "sent": "It uses 12 questions that map to four key domains.",
                    "label": 0
                },
                {
                    "sent": "Bulbar fine motor breathing and gross motor.",
                    "label": 0
                },
                {
                    "sent": "It has been successfully used up to now.",
                    "label": 0
                },
                {
                    "sent": "I might add from the LS, FRS, Arcam Delta efforts this was put forth by the Kimora Group in 2006 and they offered a way to track the rate of progression by including a time axis.",
                    "label": 0
                },
                {
                    "sent": "As you can see, sorry with the form.",
                    "label": 0
                },
                {
                    "sent": "I'm sorry the formula with the formula over here.",
                    "label": 0
                },
                {
                    "sent": "Now, when this was conceptualized, it was intended to be used only at the time of diagnosis, but this has now expanded to be used routinely in clinical trials to stratify patients as either fast, slow, or intermediate progressors.",
                    "label": 0
                },
                {
                    "sent": "There are, however, several problems with using the Delta FRS in this way, and in the interest of time I will speak about only the most salient ones now.",
                    "label": 0
                }
            ]
        },
        "clip_2": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "A quick an admittedly very perfunctory pub Med search actually makes my point for me excellently.",
                    "label": 0
                },
                {
                    "sent": "We know that there is no established threshold which represents an important transitional point in functional status or progression type you can see here just for papers that I picked randomly and see how each of them define slow and fast progression with different thresholds.",
                    "label": 1
                },
                {
                    "sent": "In fact, I recall a speech from earlier today that used 1.1 as the threshold, so we see that there is absolutely no agreement.",
                    "label": 0
                },
                {
                    "sent": "But let's assume for a minute that we did have this threshold.",
                    "label": 0
                },
                {
                    "sent": "This would still not rid us of our Delta.",
                    "label": 0
                },
                {
                    "sent": "FRS was simply becausw.",
                    "label": 0
                }
            ]
        },
        "clip_3": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "This graph, taken from our own cohort mapping LSF.",
                    "label": 0
                },
                {
                    "sent": "Our score LSF score against disease duration tells us what we already know owing to the large body of work that precedes my talk, we know that progression is heterogeneous.",
                    "label": 1
                },
                {
                    "sent": "It is nonlinear, but the Delta FRS presumes linearity.",
                    "label": 1
                },
                {
                    "sent": "And it doesn't stop here.",
                    "label": 0
                },
                {
                    "sent": "Not only is progression heterogeneous, it can actually vary within individuals across time and across the disease course.",
                    "label": 0
                }
            ]
        },
        "clip_4": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "We can see here 3 individuals, let's call the red one.",
                    "label": 0
                },
                {
                    "sent": "Fast intermediate is blue and slowest green.",
                    "label": 0
                },
                {
                    "sent": "You can see just for these three individuals how much the Delta FOS varies across across different months across the disease scores.",
                    "label": 0
                },
                {
                    "sent": "In fact, what's crucial is over here, how big the variation is within the first 12 months, which is actually crucial for clinical trial recruitment and the box that you are simply sums up.",
                    "label": 0
                },
                {
                    "sent": "What I am telling you, there is tremendous variation and we simply can't use the Delta FRS like this.",
                    "label": 0
                }
            ]
        },
        "clip_5": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Which is where we come in.",
                    "label": 0
                },
                {
                    "sent": "We present you two novel indices, D50 and DX, as an alternative to track progression and describe disease scores from full health, which would be hypothetically and LSF.",
                    "label": 1
                },
                {
                    "sent": "Our score of 48, which is the maximum and disease within relentlessly deteriorating score.",
                    "label": 1
                },
                {
                    "sent": "Now the D50 is simply the time taken for LSF SAR to drop to 50%, which would be a score of 24 the DX simply.",
                    "label": 0
                },
                {
                    "sent": "Refers to the slope of this decrease.",
                    "label": 0
                }
            ]
        },
        "clip_6": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Both of these indices are derived from regularly collected LSF scores.",
                    "label": 0
                },
                {
                    "sent": "As you can see in this next clip over here, I'm not sure how to so getting back I we were basically saying the D50 and DX are both ascertained from regularly regularly collected a LSF scores and we can give you a brief visualization.",
                    "label": 0
                },
                {
                    "sent": "Over here.",
                    "label": 0
                },
                {
                    "sent": "Now you can see the linearity already between D50 and DX, and this keeps building with as we include more patients now moving on well.",
                    "label": 0
                },
                {
                    "sent": "You may immediately be inclined.",
                    "label": 0
                }
            ]
        },
        "clip_7": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "I see, well, that's all very good, and that's a very nice little clip that you have.",
                    "label": 0
                },
                {
                    "sent": "But how well does this hold up if we simply don't have as many LS Fr scores an I'm sure a number of you can speak to how difficult it is to retain patients over longitudinal trials.",
                    "label": 0
                },
                {
                    "sent": "Failing health being, I suppose, the primary reason.",
                    "label": 0
                },
                {
                    "sent": "So let's take a look.",
                    "label": 0
                },
                {
                    "sent": "This is how well the linearity would hold up if I had access to only one FRS score for patient.",
                    "label": 0
                },
                {
                    "sent": "This if I had two scores, if I had.",
                    "label": 0
                },
                {
                    "sent": "Race course, or if I had 4 scores.",
                    "label": 0
                },
                {
                    "sent": "The take home here is OK.",
                    "label": 0
                },
                {
                    "sent": "Yes, there is much more noise as the number of scores available increase.",
                    "label": 0
                },
                {
                    "sent": "But this linear relationship does not change.",
                    "label": 0
                },
                {
                    "sent": "So although we do rely on LSF scores, the model is designed in such a way that it will still work even if you don't have access to as many.",
                    "label": 0
                }
            ]
        },
        "clip_8": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Now let's go back to the same three patients that we looked at earlier when we were talking about Delta Ephorus.",
                    "label": 0
                },
                {
                    "sent": "Only this time we're going to talk about D50 and DX.",
                    "label": 0
                },
                {
                    "sent": "Now, as you would expect, our fast Progressor has a much smaller D50 than, say you're slow.",
                    "label": 0
                },
                {
                    "sent": "Progressor, almost half of it.",
                    "label": 0
                },
                {
                    "sent": "Your intermediate progressor is somewhere in between, and here you have your DX, or your rate of decrease.",
                    "label": 0
                },
                {
                    "sent": "But you may still ask the question.",
                    "label": 0
                },
                {
                    "sent": "OK, we have a new way to track progression.",
                    "label": 0
                },
                {
                    "sent": "We have a new way to describe these patients, but what about comparability?",
                    "label": 0
                },
                {
                    "sent": "Say, how do I understand the disease mechanisms that_different phases of the disease without paying heed to rate of progression?",
                    "label": 0
                },
                {
                    "sent": "How do we do it in spite differing rates of progression if we simply take these three curves?",
                    "label": 0
                },
                {
                    "sent": "I'm sorry.",
                    "label": 0
                }
            ]
        },
        "clip_9": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And then normalize the absolute months for each patient across the disease scores by their individual D50 values.",
                    "label": 1
                },
                {
                    "sent": "We immediately see they follow a similar pattern.",
                    "label": 0
                },
                {
                    "sent": "Now, it doesn't matter whether I call them fast, intermediate, slow, good, bad, they will all follow a similar pattern we see here in the first stage, the LS of the LSF score doesn't plummet.",
                    "label": 0
                },
                {
                    "sent": "Rather it starts to gradually decay, and this is approximately where patient start being rich.",
                    "label": 0
                },
                {
                    "sent": "Recruited for Childs.",
                    "label": 0
                },
                {
                    "sent": "The score goes on to eventually plateau out and we can see that you have a rather predictable pattern over here and this allows us to loosely.",
                    "label": 0
                }
            ]
        },
        "clip_10": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Classify four phases.",
                    "label": 0
                },
                {
                    "sent": "You have the early stable phase early progressive phase, late progressive phase and late stable phase.",
                    "label": 0
                },
                {
                    "sent": "Now the crucial thing about this phase classification is that it is fluid.",
                    "label": 1
                },
                {
                    "sent": "It is mathematically derived from D50 values.",
                    "label": 0
                },
                {
                    "sent": "So as of now our analysis has been constricted to our cohort.",
                    "label": 0
                },
                {
                    "sent": "But say in the in the future, if we expanded this anet would an our results tell us it isn't in fact 50 by two or D53 by two we can change this to accommodate.",
                    "label": 0
                },
                {
                    "sent": "What more more patients would tell us?",
                    "label": 0
                }
            ]
        },
        "clip_11": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "We then asked ourselves a question.",
                    "label": 0
                },
                {
                    "sent": "While there are other staging systems already, we have the clinical King staging system.",
                    "label": 0
                },
                {
                    "sent": "We have the functional my to staging system.",
                    "label": 0
                },
                {
                    "sent": "Where do we fit into this picture?",
                    "label": 0
                },
                {
                    "sent": "How can we understand our model in the context of these models?",
                    "label": 0
                },
                {
                    "sent": "Now if you see here, we simply took 20 patients from our cohort and we manually stage them to both to either King stages or mitosis stages for both.",
                    "label": 0
                },
                {
                    "sent": "For all of these patients, we calculated something called milestone timing.",
                    "label": 1
                },
                {
                    "sent": "Now, this is simply the time taken to reach a particular stage or phase as a proportion of the total disease duration.",
                    "label": 1
                },
                {
                    "sent": "The reason we kept it to 20 is because such a calculation is of course only possible with people who have traversed the entire disease scores or died.",
                    "label": 0
                },
                {
                    "sent": "Now what you see immediately is that there is more agreement between the D50 system and the might or system.",
                    "label": 0
                },
                {
                    "sent": "Now this is expected because these are both functional systems that are that use a LSF scores as their basis.",
                    "label": 0
                },
                {
                    "sent": "What you also see as is at both of these systems seem to lag behind the King system.",
                    "label": 0
                },
                {
                    "sent": "Simply you would reach phases later if you use the D50 or might or system.",
                    "label": 0
                },
                {
                    "sent": "This is also this is understandable because the King system reflects disease burden.",
                    "label": 0
                },
                {
                    "sent": "Clinical spread so naturally functional engagement follows anatomical involvement.",
                    "label": 0
                },
                {
                    "sent": "This is what we see.",
                    "label": 0
                },
                {
                    "sent": "We also notice that it was difficult for us to explicitly demonstrate.",
                    "label": 0
                },
                {
                    "sent": "Sorry, this doesn't a stage one for the Kings.",
                    "label": 0
                },
                {
                    "sent": "For the King system, and this is something the authors themselves noted as well by the time patients present, they are typically already at stage two where there is already involvement in the second region.",
                    "label": 0
                },
                {
                    "sent": "So moving on.",
                    "label": 0
                }
            ]
        },
        "clip_12": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So what are our key takeaways from here?",
                    "label": 0
                },
                {
                    "sent": "We know the D50 and DX are highly linear, which tells us D50 can act as a standalone parameter.",
                    "label": 1
                },
                {
                    "sent": "It's accessible and it's destructive, and it's easy to use.",
                    "label": 0
                },
                {
                    "sent": "More importantly, you may ask, well, can you give me something more robust in that we also see the D50 correlates very well with survival, which is the endpoint of choice in most clinical trials.",
                    "label": 0
                },
                {
                    "sent": "We also see.",
                    "label": 0
                },
                {
                    "sent": "That D50 and Delta FRS correlate very well as well.",
                    "label": 0
                },
                {
                    "sent": "Now this over here is Delta FRS that was recorded for patients when they first presented and this over here is Delta FRS.",
                    "label": 0
                },
                {
                    "sent": "Towards the end of the disease scores for them.",
                    "label": 0
                },
                {
                    "sent": "Now this first graph simply sums up what I already told you earlier in the presentation that there is tremendous variation in Del Dia for us if I simply transform these Delta FOS values, say if I did this one over Delta FRS and then looked.",
                    "label": 0
                },
                {
                    "sent": "At this correlation with D50 you see immediately a nice clean linear relationship, and again it correlates much better with the Delta FRS towards the end of the patients disease scores.",
                    "label": 0
                },
                {
                    "sent": "Now what is crucial is that sampling.",
                    "label": 0
                },
                {
                    "sent": "Say if I took a clinical sample at any point of the patients disease scores, it can always be viewed in context of the patients D50 rather than relying on Delta FOS, which may have changed at any point in the disease course.",
                    "label": 0
                }
            ]
        },
        "clip_13": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Now you may ask what is well, what's the take home message?",
                    "label": 0
                },
                {
                    "sent": "How do we use this?",
                    "label": 0
                },
                {
                    "sent": "What do we do with it?",
                    "label": 0
                },
                {
                    "sent": "First of all, I have, as we've already seen, you can map and describe disease scores with mathematically fluid phases.",
                    "label": 1
                },
                {
                    "sent": "The D50 provides value over and above raw Fr S scores for disease progression.",
                    "label": 1
                },
                {
                    "sent": "We also know that there's increased analytical utility simply because it is such an easy endpoint for researchers to use.",
                    "label": 0
                },
                {
                    "sent": "And finally, in what is most relevant for our group is biomarker development and testing, and this is something we are actively doing within our own group.",
                    "label": 0
                },
                {
                    "sent": "For example, our recent work.",
                    "label": 0
                },
                {
                    "sent": "This was published in neurology as well.",
                    "label": 0
                },
                {
                    "sent": "Looked at how neurofilament levels are distributed across different phases of the disease and how it correlate's with the 15 you can see here that there is a difference between phase one and phase two.",
                    "label": 0
                },
                {
                    "sent": "Other other members of our group are looking at dry biomarkers in your image Ng markers to see how white matter may change a white matter.",
                    "label": 0
                },
                {
                    "sent": "Changes are different in either phase one or phase two of the disease.",
                    "label": 0
                },
                {
                    "sent": "For example.",
                    "label": 0
                },
                {
                    "sent": "Over here we see the changes are restricted more to the subcortical motor regions in the brain stem, whereas in phase two the later phase it starts to become more parietal and frontal.",
                    "label": 1
                },
                {
                    "sent": "Finally, and I think crucially for everyone here we can understand disease mechanisms if in different phases.",
                    "label": 0
                },
                {
                    "sent": "We know that there are different pathogenic mechanisms at play.",
                    "label": 0
                },
                {
                    "sent": "Early in disease and later in the disease.",
                    "label": 0
                },
                {
                    "sent": "And now we now have a way to understand them and study them.",
                    "label": 0
                }
            ]
        },
        "clip_14": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Finally, open questions and things that we're still looking to do.",
                    "label": 1
                },
                {
                    "sent": "Of course, our first goal would be to expand the cohort we used to drive these indices and also replicated with much larger cohorts.",
                    "label": 0
                },
                {
                    "sent": "We would also be interested in establishing actual mathematical cut offs for fast versus slow, for example, at what D50 value would I consider you to be a fast progressor, an intermediate progressor or slow progressor?",
                    "label": 1
                },
                {
                    "sent": "We would also like to investigate the utility of these indices in clinical trial populations an genreless populations we also think.",
                    "label": 1
                },
                {
                    "sent": "It would be worthwhile to further understand the role our system plays in the context of other current staging systems.",
                    "label": 0
                },
                {
                    "sent": "We would also think we also think it would be relevant to apply stratification and stratify patients by say, for example site of onset, phenotype, etc.",
                    "label": 1
                },
                {
                    "sent": "And finally we would like to test relation to other clinical factors.",
                    "label": 1
                },
                {
                    "sent": "How does D50 correspond to muscle strength, quality of life, forced vital capacity or cognitive decline?",
                    "label": 0
                },
                {
                    "sent": "We are also taking any suggestions for other than D50 Jena system.",
                    "label": 0
                },
                {
                    "sent": "We would be happy to hear them.",
                    "label": 0
                }
            ]
        },
        "clip_15": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Acknowledgements so I would of course like to thank our funding bodies an all of our collaborators I would like to thank my supervisor, Doctor Union Gross Kreutz, my colleagues, Doctor Beatrice Tube, and Orphan Vagina for their support.",
                    "label": 0
                },
                {
                    "sent": "Our clinical nurses and obviously our patients without whom none of this work would be possible.",
                    "label": 0
                },
                {
                    "sent": "Thank you.",
                    "label": 0
                }
            ]
        }
    }
}